These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15754453)

  • 1. Avoid PPIs with atazanavir.
    AIDS Clin Care; 2005 Feb; 17(2):18. PubMed ID: 15754453
    [No Abstract]   [Full Text] [Related]  

  • 2. Revised package insert for atazanavir.
    Sax PE
    AIDS Clin Care; 2008 Mar; 20(3):23. PubMed ID: 18399014
    [No Abstract]   [Full Text] [Related]  

  • 3. Atazanavir: a novel inhibitor of HIV-protease in haemodialysis.
    Izzedine H; Launay-Vacher V; Peytavin G; Valantin MA; Deray G
    Nephrol Dial Transplant; 2005 Apr; 20(4):852-3. PubMed ID: 15772278
    [No Abstract]   [Full Text] [Related]  

  • 4. [New data on atazanavir/r]].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():81-3. PubMed ID: 16385887
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.
    Sahloff EG; Duggan JM
    Ann Pharmacother; 2006 Oct; 40(10):1731-6. PubMed ID: 16968825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atazanavir (Reyataz) and emtricitabine (Emtriva) for HIV infection.
    Med Lett Drugs Ther; 2003 Nov; 45(1169):90-2. PubMed ID: 14603099
    [No Abstract]   [Full Text] [Related]  

  • 7. Atazanavir not to be used with proton pump inhibitors.
    AIDS Patient Care STDS; 2005 Feb; 19(2):128. PubMed ID: 15747429
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA notifications. BMS issues letter about omeprazole.
    AIDS Alert; 2005 Apr; 20(4):45-6. PubMed ID: 15841529
    [No Abstract]   [Full Text] [Related]  

  • 9. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers.
    Khanlou H; Farthing C
    J Acquir Immune Defic Syndr; 2005 Aug; 39(4):503. PubMed ID: 16010179
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.
    Tomilo DL; Smith PF; Ogundele AB; Difrancesco R; Berenson CS; Eberhardt E; Bednarczyk E; Morse GD
    Pharmacotherapy; 2006 Mar; 26(3):341-6. PubMed ID: 16503713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
    Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
    J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
    Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM
    J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
    Keiser PH; Nassar N
    Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
    Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New dosing regimen for atazanavir.
    AIDS Patient Care STDS; 2004 Sep; 18(9):548-9. PubMed ID: 15630777
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients.
    Panhard X; Taburet AM; Piketti C; Mentré F
    Stat Med; 2007 Mar; 26(6):1268-84. PubMed ID: 16810714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrocardiographic changes in HIV-infected, drug experienced patients treated with atazanavir.
    Mahnke L; Child M; Satin L; Persson A; Bertz R; Lawrence J
    AIDS; 2008 Aug; 22(13):1698. PubMed ID: 18670241
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug interactions. Is atazanavir best when boosted with ritonavir?
    TreatmentUpdate; 2006; 18(3):3. PubMed ID: 17209237
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.